Clareo Health | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Northwell Health
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years of age or older.
Documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA).
Circumscribed tumor recurrence with less than 3.5 cm greatest diameter
Patients with histologically confirmed low-grade brain tumor relapse with an enhancing tumor on MRI will be evaluated for toxicity only.
Patients must have at least one confirmed and evaluable tumor site.
Patients must have a Karnofsky performance status 70% (or the equivalent ECOG level of 0-2)
Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period.
You may not be if
Women who are pregnant or lactating.
Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring.
